Memory deficits are personally devastating and represent a large societal unmet need. Over 20 million Americans currently suffer from memory loss due to traumatic brain injury, mild cognitive impairment, and Alzheimer’s disease. Nia’s technology has the potential to help these patients by improving memory, reducing disability and increasing productivity.
Nia Therapeutics is developing precision brain stimulation therapies to treat memory loss due to brain injury and degenerative disease. Nia’s technology was developed at the University of Pennsylvania with funding from DARPA. Our team has shown that when stimulation is delivered to a specific part of the brain (the temporal lobe) when memory is predicted to fail, it can significantly improve memory performance.
Our artificial intelligence technology identifies the unique patterns of brain activity in each patient that predict memory performance. The device then continuously monitors the brain from moment to moment, delivering stimulation as needed to keep each patient in the zone of good memory performance.
The Nia team is currently conducting preclinical testing of our device before seeking approval from FDA for our first clinical trial for patients with memory loss due to traumatic brain injury